All News

The electronic revolution in clinical trials is still a work in progress, but researchers say it's time to bring EDC to the preclinical world.

A new understanding about how one class of bacteria protects itself from the environment could dramatically cut tuberculosis treatment time.

Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year-if you like roller coasters.

Some people are infected by HIV strains that are already resistant to FDA-approved drugs because they were transmitted by someone who developed resistance while receiving antiretroviral therapy. As a result, these patients often fail therapy.

Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and-at last-innovative mechanisms for troublesome targets.

PharmExec's 2005 Pharma Knowledge Quiz

The biggest threat to the success of polio eradication is Nigeria, where the immunization program was suspended on religious grounds in some parts of the country in 2003 and 2004.

Find out how you did on our December 2005 quiz.

Pargluva was a bad bet from early on. Analysts say so. Can BMS still save face?

A look at what the editors of Pharmaceutical Representative have planned for 2006.

Legal experts analyze the differences between the first two Vioxx trials and what allowed Merck to be successful this time around. They also offer insight about what to expect going forward.

The Critical Path is alive and well, as demonstrated by an agreement between FDA and Massachusetts-based BG Medicine to identify molecules associated with liver toxicity in animal trials.

PharmRep06Rates

PharmRep06Cal

PharmRep06CalRates

PhRMA Guiding Principle number 10 calls for the banishment of reminder ads. While there are many reasons why drug ads truly advance the public health, there are no good arguments for why reminder ads advance public health in any way.

Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.

Merck and GSK’s cervical cancer vaccines promise great benefits to women-but there are several key hurdles to clear before the drugs can become the blockbusters the companies are predicting. Analysts debate how long it will take it will take to overcome these obstacles.

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

Thomson CenterWatch recently launched a content management service to assist sponsors in complying with the latest requirements for clinical trial transparency. This web based program serves as a tool for sponsors to register their active clinical trials and publish their clinical trial results while following the data field guidelines established by clinicaltrials.gov and the World Health Organization and ICMJE.

A look at what the advent of generic antiretroviral drugs could mean for the industry.

ABthrax takes advantage of new knowledge about anthrax to fight the bacteria’s lethal toxin.

Wolters Kluwer Health is the professional’s first choice for knowledge-based information services and decision-support tools for the pharmaceutical, biotechnology and life science industries.

Schizophrenia experts interpret the result of an extensive head-to-head comparison of five treatments. Schizophrenia patients frequently change or discontinue treatments. The jury is out on some side effects.

Analysis of a new report that says safety-related product withdrawals have not increased since the approval process sped up in the 1990s.

Scientists at the University of Michigan found a brain mechanism that increases the release of pain-fighting endorphins when the subject was given a placebo. The implication? Better clinical trials, and maybe, new methods of pain relief, researchers say.

An ingenious pharmacogenetic test from Third Wave Technologies tests for the presence of a genetic change that inhibits metabolism of irinotecan. Oncology specialists explain how it works, and why it matters.

Legal experts play Monday-morning quarterback with Merck's first Vioxx loss. The lessons, they say: learn to present science better, pay attention to jury emotion and, oh yes, worry about shareholder lawsuits.